Ensuring that Zentiva has the necessary strategy, skills, competencies, capabilities and people to operate independently as a “leading European generics player” is a key priority, the company’s head, Patrick Aghanian, told Generics bulletin as the firm started life as an independent company under the ownership of private-equity investor Advent International.
Having on 30 September completed the €1.9 billion (US$2.2 billion) acquisition of Zentiva, just ahead of the earliest scheduled timepoint...
